Microbot Medical Inc.
MBOT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MBOT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MBOT
Microbot Medical Inc. is a pre-commercialization medical robotics company developing the LIBERTY® Endovascular Robotic System for use in peripheral vascular interventions, with ongoing U.S. market preparation and limited revenue to date.
Key risk: Limited revenue and ongoing losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Microbot Medical Inc. is a pre-commercialization medical robotics company developing the LIBERTY® Endovascular Robotic System for use in peripheral vascular interventions, with ongoing U.S. market preparation and limited revenue to date.
- Microbot Medical is focused on the LIBERTY® Endovascular Robotic System for procedures including Prostate Artery Embolization and Uterine Fibroid Embolization [sec · filed 2026-04-13].
- The company had cash equivalents and marketable securities of approximately $67,367 as of June 30, 2026, excluding restricted cash [sec_mda · as of 2026-08-11].
- Net cash used in operating activities was $10,042,000 for the six months ended June 30, 2026 [sec_mda · as of 2026-08-11].
- The company has expanded its U.S. sales footprint from four to eight territories, targeting 12 territories by end of 2026 [sec · filed 2026-04-13].
- Management believes available funds are sufficient for operations for more than one year as of the filing date of the Quarterly Report on Form 10-Q [sec_mda · as of 2026-08-11].
What works
- The company is actively expanding its U.S. commercial team and sales territories, indicating progress toward full market release [sec · filed 2026-04-13].
- Management has stated that current funds are sufficient to support operations for more than twelve months, providing near-term financial stability [sec_mda · as of 2026-08-11].
What to weigh
- The company has not yet generated significant revenue from operations and expects to continue incurring losses for the foreseeable future [sec_mda · as of 2026-08-11].
- Cash used in operating activities increased to $10,042,000 in the first half of 2026 from $5,447,000 in the same period of 2025, reflecting rising costs [sec_mda · as of 2026-08-11].
- The company faces potential geopolitical risks related to its Israel-based activities, including material imports and negative international perception [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
The company is preparing for full U.S. market release by expanding its commercial team and sales territories.
“In preparation for the full market release in the U.S., the Company has further enhanced its commercial team core capabilities by adding salespeople in key locations and broadening its sales footprint from four to eight sales territories, with a goal of having 12 territories across the U.S. by the end of 2026.”
SEC filings · April 13, 2026
The company expects to incur significant losses for the foreseeable future.
“The Company expects to incur significant losses for the foreseeable future as it conducts manufacturing operations, sales and marketing activities for its current product and continues its research and development of any other future product candidates”
SEC MD&A · August 11, 2026
Management believes current funds are sufficient for more than one year of operations.
“management believes we have sufficient funds for our operations for in excess of one year.”
SEC MD&A · August 11, 2026
The company's cash position as of June 30, 2026 was approximately $67,367 excluding restricted cash.
“As of June 30, 2026, the Company had cash equivalents and marketable securities balance of approximately $ 67,367 , excluding restricted cash.”
SEC MD&A · August 11, 2026
Risks & what to watch (3)›
Key risks
- Limited revenue and ongoing losses — The company has not generated significant revenue and expects continued losses due to R&D and commercialization costs [sec_mda · as of 2026-08-11].
- Geopolitical risk from Israel operations — Operations in Israel face risks from regional conflict, including material import disruptions and negative international perception [sec_mda · as of 2026-08-11].
- Dependence on future capital raises — The company may need additional debt or equity financing to support growth, which is subject to market conditions [sec_mda · as of 2026-08-11].
What to watch
- Progress toward the goal of 12 U.S. sales territories by end of 2026 [sec · filed 2026-04-13].
- Any updates on regulatory clearances or approvals for the LIBERTY® System [sec_mda · as of 2026-08-11].
- Changes in cash burn rate and operating cash flows in upcoming quarters [sec_mda · as of 2026-08-11].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Microbot Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Microbot Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
39.6 months
D/E 0.06 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$35.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 5,819,050 | $14.0M |
| susquehanna international group, llp | 1,140,707 | $2.7M |
| blackrock, inc. | 857,398 | $2.1M |
| geode capital management, llc | 760,831 | $1.8M |
| dnb asset management as | 677,498 | $1.6M |
| stifel financial corp | 573,075 | $1.4M |
| marshall wace, llp | 481,045 | $1.2M |
| ancora advisors llc | 477,080 | $1.1M |
| millennium management llc | 454,746 | $1.1M |
| vanguard fiduciary trust co | 400,225 | $965K |
Showing top 10 of 79 institutional holders of Microbot Medical Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 11.5%
- Days to cover
- 5.1
- Shares short
- 7,705,281
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MBOT short interestFrequently asked questions
What is the AI investment thesis for Microbot Medical Inc.?
Microbot Medical Inc. is a pre-commercialization medical robotics company developing the LIBERTY® Endovascular Robotic System for use in peripheral vascular interventions, with ongoing U.S. market preparation and limited revenue to date.
Who is the CEO of Microbot Medical Inc.?
Mr. Harel Gadot is the chief executive officer of Microbot Medical Inc. (MBOT).
Where is Microbot Medical Inc. headquartered?
Microbot Medical Inc. (MBOT) is headquartered in Hingham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.